Indaptus presents Phase 1 Decoy20 interim data: stable disease in all 4 patients

Indaptus Therapeutics, Inc.

All four patients in first cohort showed stable disease at 4 weeks; three had progressive disease at baseline.
Decoy20 induced transient expression of over 50 biomarkers associated with innate/adaptive anti-tumor immune responses.
Adverse events generally tolerable, resolved within 30 minutes to 3 days; drug cleared from blood in 30-120 minutes.
Peak cytokine/chemokine induction ~4-24 hours, returning to baseline by 24-48 hours, avoiding prolonged toxicity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.